▲ +38.50% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Galera Therapeutics in the last 3 months. The average price target is $15.00, with a high forecast of $21.00 and a low forecast of $9.00. The average price target represents a 38.50% upside from the last price of $10.83.
The current consensus among 1 investment analysts is to hold stock in Galera Therapeutics. This rating changed within the last month from a Buy consensus rating.
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule dismutase mimetic, which is in Phase III clinical trial for the treatment of radiation-induced severe oral mucositis in patients with head and neck cancer, as well as in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer. It is also involved in developing GC4711, which is in Phase I/II clinical trial for the treatment of pancreatic and lung cancers. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania.